Table 3.
Predictive factors of recurrence in univariate analysis.
| Recurrence | No recurrence | p | |
|---|---|---|---|
| N (%) | 21 (24.4) | 65 (75.6) | |
| Age (years) | 33.38 | 32.82 | NS |
| Sex ratio (M/F) | 6 | 1.82 | NS |
| Preoperative smoking (%) | 71.4 | 46.5 | 0.008 |
| Family history of IBD (%) | 19 | 6.2 | NS |
| BMI (kg/m2) | 19.47 ± 2.55 | 19.70 ± 3.07 | NS |
| CRP (mg/l) | 62.92 ± 44.8 | 58.34 ± 23.89 | NS |
| Behavior Montreal (B1/B2/B3) | 9.5/52.3/38.1 | 24.6/72.3/35.3 | NS |
| Localization (L1: ileal/L3: ileocolonic) | 71.4/28.6 | 61.5/38.5 | 0.001 |
| Duration of Crohn’s disease (months) | 18.02 | 11.22 | NS |
| Active Crohn’s disease (CDAI > 150) (%) | 57.14 | 26.15 | 0.004 |
| Average length of resection (cm) | 11.42 | 18.70 | NS |
| Duration diagnosis-surgery <9.5 months, n (%) | 17 (81) | 35 (53.8) | 0.027 |
| Myenteric nerve hyperplasia, n (%) | 8 (25) | 24 (75) | NS |
| Resection margins <2 cm, n (%) | 16 (76.2) | 21 (32.3) | 0.005 |
| Postoperative treatment AZA/5ASA/Other, n (%) | 8/5/2 (38.1/23.8/9.5) | 31/12/9 (47.6/18.4/13.9) | NS |
AZA, Azathioprine; 5ASA, 5 aminosalicylates; BMI, body mass index; CDAI, Crohn’s Disease Activity Index; CRP, c-reactive protein; IBD, Inflammatory bowel disease; NS, Non significant.